Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Safety and efficacy of first-line dacomitinib in Japanese patients with advanced non-small cell lung cancer.

Cancer science - 1 May 2020

Nishio Makoto, Kato Terufumi, Niho Seiji, Yamamoto Noboru, Takahashi Toshiaki, Nogami Naoyuki, Kaneda Hiroyasu, Fujita Yuka, Wilner Keith, Yoshida Mizuki, Isozaki Mitsuhiro, Wada Shinsuke, Tsuji Fumito, Nakagawa Kazuhiko

Abstract excerpt

In a subgroup of Japanese patients in the ARCHER 1050 randomized phase 3 trial, we evaluated the efficacy and safety and determined the effects of dose modifications on adverse events (AE) and therapy management of first-line oral dacomitinib 45 mg compared with oral gefitinib 250 mg, each once daily in 28-d cycles, in patients with EGFR-activating mutation-positive (EGFR-positive; exon 19 deletion or exon 21...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Dose-Response Relationship, Drug

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug-Related Side Effects and Adverse Reactions

Share to Gefitinib

Share to Progression-Free Survival

Share to Protein Kinase Inhibitors

Share to Quinazolinones

Source

Open in PubMed Open full text

Identifiers

PMID: 32159882
DOI: 10.1111/cas.14384
PMCID: PMC7226281

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Safety and efficacy of first-line dacomitinib in Japanese patients with advanced non-small cell lung cancer.PMID 32159882Read ↗

Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.Semantic proximity Read ↗

Safety and efficacy of first-line dacomitinib in Asian patients with EGFR mutation-positive non-small cell lung cancer: Results from a randomized, open-label, phase 3 trial (ARCHER 1050).Semantic proximity Read ↗

Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations.Semantic proximity Read ↗

Clinical efficacy of dacomitinib in rechallenge setting for patients with epidermal growth factor receptor mutant non-small cell lung cancer: A multicenter retrospective analysis (TOPGAN2020-02).Semantic proximity Read ↗

Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations.Semantic proximity Read ↗

Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial.Semantic proximity Read ↗

Is there a role for dacomitinib, a second-generation irreversible inhibitor of the epidermal-growth factor receptor tyrosine kinase, in advanced non-small cell lung cancer?Semantic proximity Read ↗

The difference between dacomitinib and afatinib in effectiveness and safety in first-line treatment of patients with advanced EGFR-mutant non-small cell lung cancer: a real-world observational study.Semantic proximity Read ↗

Real-world data of dacomitinib as first-line treatment for patients with EGFR-mutant non-small-cell lung cancer.Semantic proximity Read ↗

Efficacy in patients with EGFR-positive non-small-cell lung cancer treated with dacomitinib who had skin adverse events: post hoc analyses from ARCHER 1050.Semantic proximity Read ↗

Prophylactic treatment of dacomitinib-induced skin toxicities in epidermal growth factor receptor-mutated non-small-cell lung cancer: A multicenter, Phase II trial.Semantic proximity Read ↗

Dacomitinib for the treatment of advanced or metastatic non-small-cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.